Kumamoto, Japan

Masayo Ueno


 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2021

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Masayo Ueno: Innovator in Antibody Development

Introduction

Masayo Ueno is a prominent inventor based in Kumamoto, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of human antibodies. With a total of three patents to her name, Ueno's work focuses on innovative solutions for medical applications.

Latest Patents

Ueno's latest patents include the "Anti-transthyretin human antibody" and the "Anti-transthyretin humanized antibody." The first patent describes a human antibody that comprises a complementarity determining region of an H chain and an L chain, specifically designed to bind to transthyretin (TTR) with structural changes. This antibody has the potential to inhibit the fibrillization of TTR, making it suitable for application in the human body. The second patent outlines a humanized antibody with similar properties, emphasizing its effectiveness in binding to TTR and its applicability in human medicine.

Career Highlights

Throughout her career, Masayo Ueno has worked with notable organizations such as Km Biologics Co., Ltd. and Kumamoto University. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community.

Collaborations

Ueno has collaborated with esteemed colleagues, including Akihiko Hosoi and Masaharu Torikai. These partnerships have further enriched her research and innovation in the field of antibody development.

Conclusion

Masayo Ueno's work in the development of human antibodies showcases her dedication to advancing medical science. Her innovative patents and collaborations highlight her significant impact in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…